Reconceptualizing Long-Term Opioid Therapy and its Deprescribing During an Opioid Crisis

This asynchronous course, Reconceptualizing Long-Term Opioid Therapy and Its Deprescribing During an Opioid Crisis, explores current evidence and strategies for managing and tapering long-term opioid therapy in the context of the ongoing opioid epidemic. The course addresses clinical, ethical, and policy considerations in deprescribing, with a focus on patient-centered care, risk mitigation, and improving health outcomes. Designed for healthcare professionals, the training emphasizes practical tools for navigating complex cases and fostering collaborative decision-making in chronic pain management.

(Agenda will be discussed at the beginning of the recorded asynchronous content)

There is no commercial support for this activity.

Activity Type: Enduring Material, Asynchronous Continuing Education Activity

Method of Participation: Registration for this activity is through CloudCME (Registration tab above). For cancellations, email [email protected]. Rutgers Health reserves the right to modify the activity content, faculty, and activities and reserves the right to cancel this activity if necessary. There is no fee to attend this event. Participants must attend the educational session (Asynchronous) in their entirety and complete the post-activity evaluation in Rutgers Health CloudCME to receive continuing education credit and a certificate of attendance. CE credits and certificates will be available for 60 days after the event due to accreditation reporting compliance practices.

In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE: This activity is awarded 1.0 ANCC contact hours. Nurses should only claim those contact hours actually spent participating in the activity.

This asynchronous course, Reconceptualizing Long-Term Opioid Therapy and Its Deprescribing During an Opioid Crisis, explores current evidence and strategies for managing and tapering long-term opioid therapy in the context of the ongoing opioid epidemic. The course addresses clinical, ethical, and policy considerations in deprescribing, with a focus on patient-centered care, risk mitigation, and improving health outcomes. Designed for healthcare professionals, the training emphasizes practical tools for navigating complex cases and fostering collaborative decision-making in chronic pain management.

Presenter
Ajay Manhapra, MD
Section Chief, Pain Medicine, Hampton VA Medical Center, Hampton, VA
Research Scientist, New England MIRECC, West Haven, CT
Lecturer in Psychiatry, Yale School of Medicine, New Haven, CT
Assistant Professor in PM&R and Psychiatry, Eastern Virginia Medical School (EVMS), Norfolk, VA

Peer Review Statement
In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, Rutgers Health has resolved all potential and real conflicts of interest through content review by non-conflicted, qualified reviewers. This activity was peer-reviewed for relevance, accuracy of content, and balance of presentation by: Michele Miller, MSN, RN, Vice President, and Keith Stowell, MD, Chief Medical Officer for Rutgers Health.

Disclosure:
In accordance with the disclosure policies of Rutgers and to conform with Joint Accreditation requirements and FDA guidelines, individuals in a position to control the content of this education activity are required to disclose to the activity participants: the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 24 months; and the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device that is not yet approved.

Faculty Disclosure
Dr. Ajay Manhapra has no relevant financial relationships to disclose.

Peer Reviewers
Michele Miller, MSN, RN, and Keith Stowell, MD, have no relevant financial relationships to disclose.

Planners
The following planners have no relevant financial relationships to disclose:
Jennifer Sorensen
Patricia Dooley-Budsock

Off-Label/Investigational Use Disclosure:
Faculty are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

Content Disclaimer:
The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of any manufacturer of pharmaceuticals or devices, Rutgers University, or the New Jersey Department of Children and Families.

It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products or procedures before using them in clinical practice.

Copyright © 2025. Rutgers Health. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without written permission from Rutgers.

Questions:
Please direct content, CE-related, or technical questions to Rutgers UBHC (CCE) at [email protected].

Mitigation of Relevant Financial Relationships